Human antibodies to SARS-CoV2 for the prophylaxis and therapy of COVID-19 (CoVER-Ab)

  • Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Total publications:1 publications

Grant number: 01KI2043A

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Principle Investigator

  • Research Location

    Germany, Europe
  • Lead Research Institution

    Universität Erlangen
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details


  • Broad Policy Alignment


  • Age Group


  • Vulnerable Population


  • Occupations of Interest



Given the urgent need for prophylaxis and therapy of severe CoVID-19 the project aims to rapidly identify neutralizing human antibodies (nAb) against SARS-CoV2. Antibodies will be derived from immunoglobulin heavy and light chain pairs of plasmablasts of reconvalescent CoVID-19 patients and from immunized mice, that are transgenic for the human immunoglobulin repertoire. Antibodies will be screened for binding to the S protein of SARS-CoV2 and selected based on their efficacy in SARS-CoV2 neutralization assays. Selected nAbs will be tested for efficacy and potential disease enhancement in a mouse model for pre- and post-exposure prophylaxis and in a pre-exposure non-human primate model. Partnerships for parallel clinical development will be formed as soon as the first nAb has been identified.

Publicationslinked via Europe PMC

Last Updated:41 minutes ago

View all publications at Europe PMC

A surrogate cell-based SARS-CoV-2 spike blocking assay.